Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06507878

Conditions

Thyroid Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.

Conditions

Thyroid Cancer

Study ID

NCT06507878

Start date

Dec 5, 2024

Status verified date

Mar, 2026

Completion date

Jul 1, 2034

Anticipated

Primary completion date

Jul 1, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

All adult patients aged 18 years or older (with the exception of certain external participant countries where the legal adult age may be different; for example in Singapore, adult majors are defined by age 21 and older) with anaplastic thyroid cancer or poorly differentiated thyroid cancer as their clinical and/ or histological diagnosis will be included.

Exclusion Criteria:

Patients who do not have anaplastic thyroid cancer or poorly differentiated thyroid cancer on their tumor tissue would be excluded.

Study Design

Enrollment

459 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Overall Survival [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts and Locations

Central contacts

Priyanka C Iyer, MBBS

(832) 291-6069piyer@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Priyanka C Iyer, MBBS

832-291-6069piyer@mdanderson.org

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Mar 12, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-03-12.